NSE
Concord Biotech LimitedCONCORDBIO
Concord Biotech Limited is a biotechnology company that develops and manufactures diagnostic reagents, vaccines, and other healthcare products.
| Key products | Diagnostic Reagents, Vaccines |
|---|---|
| Geography | India, Middle East, Africa |
| Competitors | SRL Ltd, Biocon Ltd |
AI-generated overview — verify before relying on it.
Net institutional flow
+₹331 Cr
Institutional buyers
2 in / 0 out
High-impact filings
1 · tilt Bullish
Next corporate action
—
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | CONCORDBIOThis | — | — | 1 | +1 | — | — |
| 2 | ACMESOLAR | — | — | — | — | +3 | 6 |
| 3 | AADHARHFC | — | — | — | — | — | — |
| 4 | AARTIIND | — | — | — | — | — | — |
| 5 | AAVAS | — | — | — | — | — | — |
| 6 | ACE | — | — | — | — | — | — |
| 7 | ACUTAAS | — | — | — | — | +4 | 6 |
| 8 | ABFRL | — | — | — | — | — | — |
| 9 | ABLBL | — | — | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
- 2026-06-13FilingConcord Biotech Limited has informed the Exchange about Schedule of meetInvestor Call
- 2026-06-12FilingConcord Biotech Limited has informed the Exchange regarding 'Completion of ANVISA Inspection conducted by the Updates
- 2026-06-10FilingConcord Biotech Secures Abbreviated New Drug Application (ANDA) Approval for Tofacitinib Tablets, 5 mg and 10 Order Win
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2
- 2UpdatesNeutral
Completion of ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility'.
Source PDF → - 8
No bulk/block deals for CONCORDBIO in this window.
Results & transcripts
Financial results
None yet.
News & chatter on CONCORDBIO
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.